B2i Digital

The team at B2i Digital is pleased to highlight the upcoming Life Sciences Virtual Investor Forum taking place on December 11, 2025. Register: https://lnkd.in/er2WjPAg As the Official Marketing Partner for Virtual Investor Conferences (VIC), B2i Digital supports this online forum that brings together public companies and a global audience of retail and institutional investors for a full day of live, interactive corporate presentations. Yesterday’s Small Cap Growth Virtual Investor Conference is now available on replay. Investors can still watch presentations and request meetings with management at: https://lnkd.in/eY57kjSd Life Sciences Virtual Investor Forum Thursday, December 11 • 10:00 AM – 3:30 PM ET Presenting companies include: - Dave Marver, ONWARD Medical N.V. (OTCQX: ONWRY | Euronext: ONWD) - 9:30 AM - Prostatype Genomics AB Genomics (OTCQB: PGABF) - 10:00 AM - Gerald Commissiong, OS Therapies (NYSE: OSTX) - 10:30 AM - Amie Phinney, PhD, MBA, Defence Therapeutics Inc. (OTCQB: DTCFF | CSE: DTC) - 11:00 AM - Dustin Haines, EchoIQ (ASX: EIQ) - 11:30 AM EST - Thiogenesis Therapeutics, Corp. (OTCQX: TTIPF | TSXV: TTI) - 12:00 PM - Chad Pawlak, Sr., Genvor Inc. (OTCQB: GNVR) - 12:30 PM - Eric A. Adams from InMed Pharmaceuticals Inc. (NASDAQ: INM) - 2:00 PM - Jake Nichols from BioCorRx, Inc. (OTCQB: BICX) - 2:30 PM - Chris Burns FAHMS from Amplia Therapeutics Limited (OTCQB: INNMF | ASX: ATX) - 3:00 PM All public companies—whether listed on NYSE, Nasdaq, TSX, CSE, ASX, or the OTC Markets—are welcome to participate in VIC events. Conference Features • Live company presentations with Q&A • One-on-one investor–management meetings • On-demand replays for extended visibility • Real-time engagement tools connecting issuers with retail and institutional investors Virtual Investor Conferences (an OTC Markets Group Inc. property) provides an interactive platform for public companies to reach a global investor base across multiple sectors and exchanges. For more information, visit: https://lnkd.in/eR3S2ZT5 B2i Digital looks forward to supporting these virtual forums that help growth-oriented companies share their story with the investor community.

BNB Plus Corp. (Nasdaq: BNBX) announced strategic treasury growth with the acquisition of 3,349 additional BNB tokens, operational improvements at its LineaRx subsidiary, and the launch of its new corporate website and branding. BNB Plus (Nasdaq: BNBX) is a B2i Digital Featured Company. See the comprehensive profile at https://lnkd.in/ejcMGtQm. The company deployed approximately $3 million to acquire BNB at an average price of $895 per token, bringing total holdings to approximately 18,840 BNB through direct ownership and OBNB trust units. Management continues advancing its integration of DeFi-based and native Binance yield opportunities into the company’s treasury framework, targeting sustainable yield generation and enhanced balance sheet productivity. Following comprehensive restructuring earlier this year, LineaRx is expected to significantly narrow losses and approach profitability in FY26Q1 (ending December 31, 2025) while maintaining its industry-leading cell-free DNA production capabilities. The company also launched its new corporate website at BNB.plus, together with updated branding that reflects its dual mandate as both a biotechnology operator and digital asset treasury company. “We believe that executing a successful digital asset treasury strategy requires more than simply accumulating a target asset—it demands operational efficiency across every aspect of a company,” said Clay Shorrock, CEO and President of BNB Plus. “With a right-sized operating company engaged in the rapidly expanding genetic medicine and diagnostic manufacturing markets, a disciplined and strategic accumulation of BNB, and the completion of our corporate rebrand, we believe we have established a strong foundation on which to build the next chapter of shareholder value.” Read the full announcement: https://lnkd.in/eTfPCb-7 BNB Plus Corp. is led by Clay Shorrock, Chief Executive Officer and President; and Beth Jantzen, Chief Financial Officer. The company’s advisory team includes Anthony Scaramucci, Founder and Managing Partner of SkyBridge Capital, as Strategic Capital Markets Advisor; Patrick Horsman, CFA as Chief Investment Officer; Josh Kruger, as Chairman of the Board; and JR Pasch, as Strategic Advisor. To learn more about BNB Plus Corp., visit https://lnkd.in/eZc-PB4w. For investor inquiries, contact [email protected]. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.

BNB Plus Corp. (Nasdaq: BNBX) recently joined the Odyssey podcast for a wide-ranging discussion about its Digital Asset Treasury model, why the team selected BNB as a productive treasury asset, and how yield strategies are designed to increase long-term token holdings for shareholders. The trailer below introduces key themes from the conversation. BNB Plus (Nasdaq: BNBX) is a B2i Digital Featured Company. See the comprehensive profile at https://lnkd.in/eh4rTa2y. In the Odyssey roundtable, members of the BNB Plus team explain how they view a DAT structure, walk through the four core yield strategies they use within the BNB ecosystem, and discuss how productive assets like BNB can support token accumulation beyond simple buy-and-hold approaches. The discussion also touches on how the legacy biotechnology operations fit alongside the company’s BNB-focused treasury strategy. “The only reason to own a DAT is because over time, with a good team and with a productive asset like BNB, you’ll end up owning more BNB tokens over time with the DAT than you would if you just bought those tokens directly,” said Patrick Horsman, Chief Investment Officer. Watch the full Odyssey episode here: https://lnkd.in/eQWTHm_w In upcoming posts, B2i Digital will be featuring additional moments from the Odyssey podcast, highlighting Launchpool strategies, DAT structures, yield generation strategies, and more. BNB Plus Corp. is led by Clay Shorrock, Chief Executive Officer and President, and Beth Jantzen, Chief Financial Officer. The company’s advisory team includes Anthony Scaramucci, Founder and Managing Partner of SkyBridge Capital, as Strategic Capital Markets Advisor; Patrick Horsman, CFA, as Chief Investment Officer; Joshua Kruger, as Chairman of the Board; and JR Pasch, as Strategic Advisor. To learn more about BNB Plus Corp., visit https://lnkd.in/eZc-PB4w. For investor inquiries, contact [email protected]. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security

Many stroke survivors are unaware that structured vision rehabilitation programs combine multiple therapeutic approaches to support recovery. Vycor’s NovaVision division offers two complementary therapies that work together to help patients navigate the challenges of post-stroke vision changes. Vycor Medical, Inc. (OTCQB: VYCO) is a B2i Digital Venture Company. See the company’s complete profile at https://lnkd.in/eZxxWBVU. Vycor’s latest article explains how visual field stimulation and eye movement retraining address different aspects of vision disorders after stroke. As described in the article, the therapies play different roles: “Vision restoration therapy focuses on trying to improve visual field sensitivity, while saccadic therapy helps patients make better use of whatever vision they have.” Read the entire article: https://lnkd.in/euwvAf8H Vycor operates two divisions: Vycor Medical (ViewSite Brain Access System (VBAS) for neurosurgery) and NovaVision (vision rehabilitation therapies for stroke/brain injury patients). Vycor is led by CEO Peter Zachariou, President David Cantor, and CFO Adrian Liddell, each bringing extensive experience in medical technology, business development, and finance. More information is available at https://lnkd.in/eSATjP_X. For investor inquiries, please contact [email protected]. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased and currently owns shares of unrestricted VYCO stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of VYCO or any security, nor is it intended to offer any opinion on VYCO as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclosure in the Risks and Disclosures section of https://lnkd.in/dngE2d4m.

OS Therapies (NYSE American: OSTX) announced a successful pre-Marketing Authorisation Application (MAA) meeting with the UK Medicines and Healthcare Products Regulatory Agency (MHRA) regarding its Phase 2b clinical trial of OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma. OS Therapies is a B2i Digital Featured Company. View their comprehensive profile at https://lnkd.in/epFNRZQB. With MHRA alignment now achieved, the company turns to its December 11 FDA Type C meeting to finalize the biomarker statistical analysis plan before initiating data analysis. Among the highlights: • Full alignment achieved with MHRA on non-clinical, CMC (chemistry, manufacturing, and controls), and post-market authorization confirmatory study design • Biomarker data advanced as a surrogate clinical efficacy endpoint, correlating upregulated immune response markers from canine long-term survivors with 2-year overall survival data from the Phase 2b human trial—with analysis pending FDA alignment to ensure the statistical plan is pre-specified • OS Therapies reaffirmed its end-of-January 2026 timeline for MAA submission to MHRA Paul Romness, Chairman & CEO noted: “We were pleased with the insightful feedback from our colleagues at UK MHRA during yesterday’s pre-MAA meeting. Their perspective will be very helpful as we finalize preparations for our upcoming Type C Meeting with US FDA on Thursday.” See the announcement at: https://lnkd.in/eak9cvUs Led by CEO Paul Romness and an executive team that includes Christopher Acevedo (CFO), Robert Petit (Chief Medical and Scientific Officer), Jack Doll (Chief of Staff), and Gerald Commissiong (Chief Business Officer), OS Therapies is focused on advancing immunotherapies for osteosarcoma and other solid tumors. Learn more at https://lnkd.in/eaAJSfqz and visit B2i Digital for updates. For investor-related questions, please see OS Therapies’ Investor Relations page or email [email protected]. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted OSTX stock. B2i Digital, Inc. is not a broker-dealer or investment adviser. This post is for informational purposes only and is not an offer to sell or a solicitation to buy any security. Investors should conduct their own research and consult with a qualified financial adviser before making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://lnkd.in/dngE2d4m.

B2i Digital is proud to be named the Official Marketing Partner for Virtual Investor Conferences (VIC), the long-running online investor event series owned and operated by OTC Markets Group Inc. Our partnership begins this week with two upcoming events: Small Cap Growth Virtual Investor Conference – December 9, 2025 Life Sciences Virtual Investor Forum – December 11, 2025 Presenting Companies – December 9 Small Cap Growth Conference Northstar Clean Technologies Inc. Frontera Energy Corp. Dotz Nano Ltd. Ethema Health Corporation Carrier Connect Data Solutions Inc. Auxly Cannabis Group Inc DarkPulse Inc Nature's Miracle Holding Inc. Telo Genomics. CyberloQ Technologies, Inc Xtreme One Entertainment, Inc. ($XONI) Presenting Companies – December 11 Life Sciences Virtual Investor Forum Genvor Inc. (B2i Digital Featured Company) Prostatype Genomics AB Defence Therapeutics EchoIQ Ltd. Thiogenesis Therapeutics, Corp. InMed Pharmaceuticals BioCorRx, Inc. Amplia Therapeutics Limited Virtual Investor Conferences connects public companies with a global audience of individual and institutional investors through live presentations, Q&A sessions, one-on-one virtual meetings, and on-demand replays. The series enhances investor engagement for issuers across multiple U.S. and international public markets, such as NYSE, Nasdaq, TSX, CSE, ASX, LSE/AIM, Frankfurt Stock Exchange, Euronext, and OTC Markets. Event Features Include: • Live company presentations with investor Q&A • One-on-one virtual meetings • On-demand replay access • Global reach to retail and institutional investors As Marketing Partner, B2i Digital will leverage its network of more than 1.4 million investors, high-traffic website, and curated investor email list of over 100,000 recipients to help participating companies broaden their visibility and reinforce investor engagement before, during, and after each event. Investor Registration is Open: Small Cap Growth Virtual Investor Conference – December 9 https://lnkd.in/eY57kjSd Life Sciences Virtual Investor Forum – December 11 https://lnkd.in/er2WjPAg Additional information on B2i Digital’s website: B2i Digital Event Overview – December 9 Conference https://lnkd.in/ehuu_5zX B2i Digital Event Overview – December 11 Conference https://lnkd.in/ezi7FFfV